Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases.
• Relapse is common in AAV, necessitating effective reinduction therapies.

Purpose of the Study:

• To evaluate the efficacy and safety of rituximab combined with glucocorticoids for inducing remission in patients with relapsing AAV.
• To assess outcomes in a prospective observational cohort within the RITAZAREM trial.

Main Methods:

• Prospective enrollment of 188 patients with relapsing granulomatosis with polyangiitis or microscopic polyangiitis.
• Treatment with rituximab (4×375 mg/m²) and a physician-chosen higher or lower dose glucocorticoid regimen.
• Glucocorticoid dose reduction to 10 mg/day by 4 months.

Main Results:

• 90% of patients (171/188) achieved remission by 4 months.
• Only 3.2% of patients did not achieve disease control.
• Four deaths occurred during induction; 13 severe infections were reported among 27 patients with severe adverse events.

Conclusions:

• Rituximab and glucocorticoids demonstrate high efficacy in reinducing remission for relapsing AAV.
• The safety profile is consistent with previous studies.
• This approach offers a viable treatment option for patients experiencing AAV relapse.